MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

Home・Aandelen Lijst・Geron Corp

Geron Corp

Gesloten

SectorGezondheidszorg

1.69 -3.98

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.6800000000000002

Max

1.76

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -29M
Verkoop	788K 48M
Winstmarge	-60.11
Werknemers	258
EBITDA	-14M -24M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+87.86% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-21M 1.1B
Vorige openingsprijs	5.67
Vorige sluitingsprijs	1.69

Nieuwssentiment

By Acuity

43%

57%

149 / 348 Rangschikking in Healthcare

Geron Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 apr 2026, 23:36 UTC

Acquisities, Fusies, Overnames

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14 apr 2026, 23:24 UTC

Populaire aandelen

Stocks to Watch: Gloo, Broadcom, GitLab

14 apr 2026, 22:42 UTC

Acquisities, Fusies, Overnames

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14 apr 2026, 21:32 UTC

Belangrijke Marktbewegers

GitLab Shares Rise on Expanded Google Cloud Collaboration

14 apr 2026, 23:54 UTC

Marktinformatie

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower on Possible Technical Correction -- Market Talk

14 apr 2026, 22:54 UTC

Winsten

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14 apr 2026, 22:54 UTC

Winsten

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14 apr 2026, 22:54 UTC

Winsten

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14 apr 2026, 22:54 UTC

Winsten

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14 apr 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14 apr 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14 apr 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14 apr 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14 apr 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14 apr 2026, 22:14 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14 apr 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14 apr 2026, 22:12 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14 apr 2026, 22:12 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14 apr 2026, 22:10 UTC

Acquisities, Fusies, Overnames

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14 apr 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

14 apr 2026, 20:33 UTC

Acquisities, Fusies, Overnames

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 20:32 UTC

Populaire aandelen

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14 apr 2026, 19:59 UTC

Acquisities, Fusies, Overnames

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14 apr 2026, 19:38 UTC

Winsten

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 apr 2026, 19:27 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14 apr 2026, 19:21 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14 apr 2026, 19:09 UTC

Acquisities, Fusies, Overnames

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14 apr 2026, 18:30 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 apr 2026, 18:30 UTC

Marktinformatie

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Peer Vergelijking

Prijswijziging

Geron Corp Prognose

Koersdoel

By TipRanks

87.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.25 USD 87.86%

Hoogste 5 USD

Laagste 1 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Geron Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Geron Corp - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

149 / 348 Rangschikking in Gezondheidszorg

Financieel

Over Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.